Spots Global Cancer Trial Database for Assessment of Early Detection and Prognosis Based on cfDNA Methylation in Multiple Myeloma
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Assessment of Early Detection and Prognosis Based on cfDNA Methylation in Multiple Myeloma
Official Title: Assessment of Early Detection and Prognosis Based on cfDNA Methylation in Myeloma: a Proof of Concept Study
Study ID: NCT05693012
Conditions
Interventions
Study Description
Brief Summary: It is an observational, case-control study aimed at early-detection of multiple myeloma and constructing a prognostic model of multiple myeloma. The study will enroll approximately 398 participants including patients with multiple myeloma, patients with benign hematologic disorders and healthy participants.
Detailed Description:
Eligibility
Minimum Age: 40 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
National Clinical Research Center for Blood Diseases, Blood Diseases Hospital & Institute of Hematology, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, Tianjin, China
Contact Details
Name: Lugui Qiu, MD, Ph.D
Affiliation: Chinese Academy of Medical Sciences & Peking Union Medical College
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
